Circulating resistin levels and risk of multiple myeloma in three prospective cohorts

Loredana Santo, Lauren R. Teras, Graham G. Giles, Stephanie J. Weinstein, Demetrius Albanes, Ye Wang, Ruth M. Pfeiffer, Qing Lan, Nathaniel Rothman, Brenda M. Birmann, Graham A. Colditz, Michael N. Pollak, Mark P. Purdue, Jonathan N. Hofmann

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Background:Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case-control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively.Methods:We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium.Results:In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24-0.83 and 0.54; 95% CI 0.29-0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; P trend =0.03). No association was observed for women.Conclusions:This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.

Original languageEnglish
Pages (from-to)1241-1245
Number of pages5
JournalBritish Journal of Cancer
Volume117
Issue number8
DOIs
StatePublished - Oct 10 2017

Fingerprint

Dive into the research topics of 'Circulating resistin levels and risk of multiple myeloma in three prospective cohorts'. Together they form a unique fingerprint.

Cite this